Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Price Target at $129.83

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $129.8333.

DNTH has been the topic of several research analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush boosted their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Truist Financial lifted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $104.77 on Friday. The stock has a fifty day moving average of $106.93 and a 200-day moving average of $92.14. The company has a market capitalization of $5.73 billion, a PE ratio of -25.25 and a beta of 1.24. Dianthus Therapeutics has a one year low of $32.22 and a one year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. As a group, research analysts forecast that Dianthus Therapeutics will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, Director Anne McGeorge sold 7,750 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the sale, the director owned 1,250 shares in the company, valued at approximately $136,262.50. The trade was a 86.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Simon Read sold 2,778 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the sale, the director owned 2,778 shares in the company, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 253,678 shares of company stock worth $27,248,400 in the last 90 days. 3.02% of the stock is currently owned by insiders.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its stake in shares of Dianthus Therapeutics by 1,275.3% during the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after purchasing an additional 441,156 shares during the period. SummitTX Capital L.P. increased its holdings in shares of Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after acquiring an additional 12,118 shares in the last quarter. Walleye Capital LLC bought a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $1,743,000. California State Teachers Retirement System increased its position in shares of Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after acquiring an additional 24,697 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Dianthus Therapeutics by 54.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 325,440 shares of the company’s stock valued at $27,296,000 after purchasing an additional 114,767 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.